team

  Executive Management

Dr. Alan Robertson

Dr. Robertson served as the Chief Executive Officer and Managing Director of Pharmaxis Ltd. from December 1999 to March 2013, taking the company through multiple capital raisings and public listings on the Australian Stock Exchange and on the NASDAQ raising more than $350 million dollars in the US, Europe and Australia. In this role, he developed a new inhaled dry powder treatment for cystic fibrosis (Bronchitol) and an invasive bronchial challenge test for hyperactive airway disease (Aridol) to marketing approval in Australia, Europe and the USA.

Philip Daffas

Philip has a career spanning more than 25 years in the medical device and diagnostics markets. He has held global roles in the areas of infusion therapy and vascular intervention based out of Europe and the US. Roles in Australia have included VP Global Marketing at Cochlear, and General Management roles with Roche Diagnostics and Bio-Rad Laboratories.

David Lane - General Manager

David has worked at AllVascular for the past 9 years. During his tenure he has gained experience in all facets of the company including clinical trials, regulatory affairs, reimbursement, sales and marketing. David has played an integral role in developing and executing AllVascular’s business plan and building the management team to date. David manages the AllVascular team on a day-to-day basis and currently reports to the board.

 

Nyan Khin - Head Biomedical Engineer

Nyan has been at AllVascular for 6 years and has developed the specifics of AllVascular’s clinical trials including the regulatory framework. He liaises with the clinical investigators to devise the most suitable patient treatment procedures and develop feasible clinical study objectives, endpoints and study design. Nyan also leads the engineering team at AllVascular to develop new products and take them through the required regulatory testing in preparation for sale.

Scott Murphy – Design Engineer

Scott is completed his Bachelor of Engineering Honours (Biomedical) at the University of Sydney, where he graduated with First Class Honours and University Medal. His honours thesis was titled ‘Computational Analysis and Design Optimisation of Coronary Arterial Stents’. Scott subsequently joined AllVascular in 2014 as a junior biomedical engineer, where he has taken up a key role in the design, verification and validation of AllVascular medical devices.

Chris Kyung – Quality Assurance Manager/Project Engineer

Chris is a BE(CHEM)/ME(BIOM) graduate from the University of New South Sales. His honours thesis, which was titled "The Effects of Heparin Size and Charge on Cancer Cell Proliferation and Metastasis," investigated the suitability of heparin as a potential anti-cancer agent. Furthermore, he served as a research assistant at the University of New South Wales where he further developed numerous research and engineering skills.  As a QA Manager and a Project Engineer, Chris has particular interest in maintaining the company's quality management system to the requirements of ISO 13485 whilst facilitating a smooth process to develop tangible products from conceptual designs.

  Advisory Committee

Andrew Sneddon

Andrew Sneddon has been an advising AllVascular since 2014. Andrew was a partner at Price Waterhouse Coopers for 33 years. He provides strategic advice to help fast growing Australian technology companies fully exploit their technology globally. Andrew is the Chairman of TGR Bioscience, ServiveRocket Inc, Fusion Payments, Elastagen, NED at Clearview & Innate Immunotherapeutics.

Alastair Young

In1995 Alastair started Orphan Australia Pty Ltd, a specialist marketing and distribution company specialising in niche pharmaceuticals, and sold it thirteen years later when the sales were $40M and EBIT $13M to Sigma Pharmaceuticals for $130M. He has a BSc in Pharmacy and a Masters degree in Pharmaceutical Analysis from Strathclyde University in Glasgow. He completed an Executive MBA from Melbourne University in 1991.

Professor Rodney Lane

Prof. Lane is a vascular surgeon and biomedical engineer. In 2005 he developed AllVascular’s Arterial and Venous Access System and its ancillary components. The professor’s intimate knowledge of the device and systems provides the foundation for AllVascular’s product development plan.